Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech
SEOUL, South Korea, August 24, 2026 Hanmi Pharm announced an exclusive global licensing agreement with Genentech, a member of...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SEOUL, South Korea, August 24, 2026 Hanmi Pharm announced an exclusive global licensing agreement with Genentech, a member of...
PARSIPPANY, NEW JERSEY & CHICAGO, April 29, 2026 Teva Pharmaceutical Industries Ltd. has announced a definitive agreement to acquire...
Cambridge, Massachusetts & Hangzhou, China, April 20, 2026 In a significant strategic move within the biopharmaceutical industry, Biogen Inc....
